LUPIN - Lupin | Wealthrox

Lupin

LUPIN · Pharma > Pharmaceuticals & Drugs · Chairman: Manju D Gupta · MD: Nilesh Gupta · Listing date: Sept. 11, 2001 · Employees: 18573 · Mumbai · http://www.lupin.com

Stock Price vs Company Growth

1.9%

1.0%

1.8%

21.9%

38.7%

93.7%

27.3%

10y

5.8%

all

18.5%

🤔 How to analyze this graph?

Last Traded Price

₹ 2,217 1.9%

1,767

2,312

Company Overview

Sales

20,797 Cr

Growth: 14.2%

Profit after Tax

2,264 Cr

Growth: 18.2%

Large Cap

1,01,111 Cr

P/E: 44.8x

Industry P/E: 40.7x

Fundamentals

Sales (Cr)	₹ 20,797
Growth	14.2%
EBITDA	20.1%
P/S	4.9x
Dividend	0.4%
P/E	44.8x
Book Value	₹ 331
PEG Ratio	3.2x
ROE	15.9%
P/B	6.7x

Shareholding Pattern

Institutions

Life Insurance Corporation Of India

6.99 %

Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund

4.28 %

Government Pension Fund Global

1.21 %

Franklin India Focused Equity Fund

1.13 %

Icici Prudential Life Insurance Company Limited

1.13 %

Promoters

Lupin Investments Pvt Ltd

45.3 %

Manju D Gupta

0.85 %

Nilesh D Gupta

0.2 %

Anuja Gupta

0.16 %

Desh Bandhu Gupta Huf

0.14 %

Others

Rakesh Jhunjhunwala

1.6 %

Nps Trust - A/C Lic Pension Fund Sch-State Govt

1.48 %

Iepf

0.15 %

Increase Decrease No change

Company Profile Detailed

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.Products and services offered by the companyGlobal FormulationsActive Pharmaceuticals Ingredients (API)BiotechSpecialty BusinessOver The Counter (OTC)Global Manufacturing & Supply ChainAwards2007: Cardinal Health Conferred Two Awards - The ‘Trade Representative Of The Year’ And The ‘Quality Supplier Award’ To Lupin Pharmaceuticals Inc.

Belongs to (39 Indices) view more

Investors (231)

lavneet

iepf

ishares....

Followers (55)

rehan

yogesh

nitin2